Currently, PRAME is a target antigen in a clinical phase I trial evaluating multi-tumour-associated antigen-specific cytotoxic T lymphocytes in rhabdomyosarcoma (NCT02239861, TACTASOM). The gene discussed is PRAME; the disease is neoplasm.